Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
WuXi AppTec revenues slump in the first quarter
by Aayushi Pratap
May 4, 2024
| A version of this story appeared in
Volume 102, Issue 14
Shanghai-based WuXi AppTec, which is a subject of a proposed US bill that aims to cut business ties with a handful of Chinese pharmaceutical service companies, announced first-quarter sales of $1.1 billion, down 11% from the prior year. Revenues excluding those from COVID-19 commercial projects dropped 1.8%. The company expects to generate sales of over $5 billion this year despite what it calls “uncertainties in the external environment,” a possible reference to the proposed US legislation.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter